Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly?

Novo Nordisk offers dividend income and MASH upside versus Lilly's high‑growth obesity lead.

CryptoAlerta — análise de criptomoedas e mercado em tempo real